Sign In
Buy RSLS
$3.92
+0 (+0%)
At Close: Nov 13, 2025
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
07:43pm, Thursday, 14'th Nov 2024
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas St
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
04:05pm, Tuesday, 12'th Nov 2024
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
08:31am, Tuesday, 12'th Nov 2024
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Cana
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology
08:31am, Monday, 11'th Nov 2024
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments fo
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
08:31am, Thursday, 19'th Sep 2024
IRVINE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Boar
ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript
08:42pm, Thursday, 15'th Aug 2024
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller - IR Paul Hickey - President and CEO Thomas Stankovich - CFO Kr
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
08:31am, Tuesday, 13'th Aug 2024
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders
08:05am, Friday, 19'th Jul 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Li
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders
09:01am, Monday, 15'th Jul 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ReShape Lifesciences Inc. (NASDAQ: RSLS) and Vyome Therapeutics, Inc. is fair to ReShap
Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”
12:13pm, Tuesday, 09'th Jul 2024
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large mark
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
08:31am, Tuesday, 09'th Jul 2024
ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger
ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript
08:57pm, Friday, 17'th May 2024
ReShape Lifesciences, Inc. (NASDAQ:RSLS ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relatons Paul Hickey - President, CEO & Director Thoma
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 15'th May 2024
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Impleme
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
08:31am, Tuesday, 14'th May 2024
IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will re
